Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through four segments: Softgel Technologies, Biologics and Specialty Drug Delivery, Oral Drug Delivery, and Clinical Supply Services. The Softgel Technologies segment formulates, develops, and manufactures prescription and consumer soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone732-537-6200
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$2.52 billion
Profitability
Miscellaneous
Employees12,300
Next Earnings Date5/5/2020 (Estimated)
OptionableOptionable
Catalent (NYSE:CTLT) Frequently Asked Questions
What is Catalent's stock symbol?
Catalent trades on the New York Stock Exchange (NYSE) under the ticker symbol "CTLT."
How were Catalent's earnings last quarter?
Catalent Inc (NYSE:CTLT) issued its quarterly earnings data on Monday, February, 3rd. The company reported $0.45 earnings per share for the quarter, beating the Zacks' consensus estimate of $0.39 by $0.06. The business had revenue of $721.40 million for the quarter, compared to the consensus estimate of $700.81 million. Catalent had a return on equity of 15.21% and a net margin of 5.44%. The firm's revenue was up 15.8% compared to the same quarter last year. During the same period last year, the business earned $0.45 EPS. View Catalent's Earnings History.
When is Catalent's next earnings date?
What guidance has Catalent issued on next quarter's earnings?
Catalent updated its FY 2020
Pre-Market earnings guidance on Monday, February, 3rd. The company provided earnings per share (EPS) guidance of 1.92-2.06 for the period, compared to the Thomson Reuters consensus estimate of $1.97. The company issued revenue guidance of $2.87-2.95 billion, compared to the consensus revenue estimate of $2.85 billion.
What price target have analysts set for CTLT?
6 analysts have issued 12 month price targets for Catalent's shares. Their forecasts range from $49.00 to $75.00. On average, they anticipate Catalent's stock price to reach $64.00 in the next twelve months. This suggests a possible upside of 8.5% from the stock's current price. View Analyst Price Targets for Catalent.
What is the consensus analysts' recommendation for Catalent?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Catalent in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Catalent.
Has Catalent been receiving favorable news coverage?
News headlines about CTLT stock have been trending very negative on Monday, according to InfoTrie. The research firm identifies positive and negative press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Catalent earned a media sentiment score of -3.0 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View News Stories for Catalent.
Who are some of Catalent's key competitors?
Some companies that are related to Catalent include ASTELLAS PHARMA/ADR (ALPMY), Takeda Pharmaceutical (TKPYY), Shiseido (SSDOY), Alexion Pharmaceuticals (ALXN), UCB (UCBJF), GRIFOLS S A/S (GRFS), Merck KGaA (MKGAF), BioMarin Pharmaceutical (BMRN), Genmab A/S (GNMSF), GALAPAGOS NV/S (GLPG), Alnylam Pharmaceuticals (ALNY), Teva Pharmaceutical Industries (TEVA), Elanco Animal Health (ELAN), Mylan (MYL) and Beigene (BGNE).
What other stocks do shareholders of Catalent own?
Who are Catalent's key executives?
Catalent's management team includes the folowing people:
- Mr. John R. Chiminski, Chairman & CEO (Age 55)
- Mr. Wetteny N. Joseph, Sr. VP & CFO (Age 47)
- Mr. Steven L. Fasman, Sr. VP, Gen. Counsel & Corp. Sec. (Age 56)
- Mr. Jonathan Arnold, Pres of Oral Drug Delivery Bus. Unit (Age 53)
- Mr. Alessandro Maselli, Pres & COO (Age 47)
Who are Catalent's major shareholders?
Catalent's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Janus Henderson Group PLC (11.28%), Champlain Investment Partners LLC (3.31%), Franklin Resources Inc. (2.48%), State Street Corp (2.39%), Earnest Partners LLC (1.85%) and FMR LLC (1.69%). Company insiders that own Catalent stock include Alessandro Maselli, Aristippos Gennadios, Barry Littlejohns, Donald E Morel, Jr, Gregory T Lucier, John J Greisch, John R Chiminski, Lance Miyamoto, Michael J Grippo, Peter L Buzy, Ricardo Pravda, Steven L Fasman and William Downie. View Institutional Ownership Trends for Catalent.
Which major investors are selling Catalent stock?
CTLT stock was sold by a variety of institutional investors in the last quarter, including Partner Fund Management L.P., FMR LLC, Janus Henderson Group PLC, CWM LLC, GW&K Investment Management LLC, State of Tennessee Treasury Department, Loomis Sayles & Co. L P and UBS Asset Management Americas Inc.. Company insiders that have sold Catalent company stock in the last year include Alessandro Maselli, Aristippos Gennadios, Barry Littlejohns, John R Chiminski, Lance Miyamoto, Michael J Grippo, Ricardo Pravda and Steven L Fasman. View Insider Buying and Selling for Catalent.
Which major investors are buying Catalent stock?
CTLT stock was bought by a variety of institutional investors in the last quarter, including Champlain Investment Partners LLC, Westfield Capital Management Co. LP, Artisan Partners Limited Partnership, Schroder Investment Management Group, Bank of America Corp DE, Earnest Partners LLC, First Trust Advisors LP and Madison Asset Management LLC. Company insiders that have bought Catalent stock in the last two years include Donald E Morel, Jr, Gregory T Lucier, John J Greisch and Peter L Buzy. View Insider Buying and Selling for Catalent.
How do I buy shares of Catalent?
Shares of CTLT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Catalent's stock price today?
One share of CTLT stock can currently be purchased for approximately $58.98.
How big of a company is Catalent?
Catalent has a market capitalization of $8.64 billion and generates $2.52 billion in revenue each year. The company earns $137.40 million in net income (profit) each year or $1.62 on an earnings per share basis. Catalent employs 12,300 workers across the globe.View Additional Information About Catalent.
What is Catalent's official website?
How can I contact Catalent?
Catalent's mailing address is 14 SCHOOLHOUSE ROAD, SOMERSET NJ, 08873. The company can be reached via phone at 732-537-6200 or via email at [email protected]
MarketBeat Community Rating for Catalent (NYSE CTLT)
MarketBeat's community ratings are surveys of what our community members think about Catalent and other stocks. Vote "Outperform" if you believe CTLT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CTLT will underperform the S&P 500 over the long term. You may vote once every thirty days.
